Speciality pharmaceutical development firm AGI Therapeutics has announced the departure of the president of its US operations, Dr David Young.

Dr Young will remain in his capacity as a director of the board of AGI Therapeutics.

Also set to leave the company is Dr Sian Bigora, vice president of clinical research and regulatory affairs. Dr John Devane, chief executive of AGI Therapeutics, thanked both for their contribution to the company.

AGI commons shares are listed on the Irish Enterprise Exchange of the Irish Stock Market as AGI.